Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

NCT06439589 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: HRS2398
DRUG: Adebrelimab

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.